Advances in multi-omics study of biomarkers of glycolipid metabolism disorder DOI Creative Commons
Xinyi Fang, Runyu Miao, Jiahua Wei

et al.

Computational and Structural Biotechnology Journal, Journal Year: 2022, Volume and Issue: 20, P. 5935 - 5951

Published: Jan. 1, 2022

Glycolipid metabolism disorder are major threats to human health and life. Genetic, environmental, psychological, cellular, molecular factors contribute their pathogenesis. Several studies demonstrated that neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, gut microbiota dysbiosis core pathological links associated with it. However, the underlying mechanisms therapeutic targets of glycolipid remain be elucidated. Progress in high-throughput technologies has helped clarify pathophysiology disorder. In present review, we explored ways means by which genomics, transcriptomics, proteomics, metabolomics, microbiomics could help identify novel candidate biomarkers for clinical management We also discuss limitations recommended future research directions multi-omics on these diseases.

Language: Английский

Trends in insulin resistance: insights into mechanisms and therapeutic strategy DOI Creative Commons

Mengwei Li,

Xiaowei Chi, Ying Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: July 6, 2022

The centenary of insulin discovery represents an important opportunity to transform diabetes from a fatal diagnosis into medically manageable chronic condition. Insulin is key peptide hormone and mediates the systemic glucose metabolism in different tissues. resistance (IR) disordered biological response for stimulation through disruption molecular pathways target Acquired conditions genetic factors have been implicated IR. Recent biochemical studies suggest that dysregulated metabolic mediators released by adipose tissue including adipokines, cytokines, chemokines, excess lipids toxic lipid metabolites promote IR other associated with several groups abnormal syndromes include obesity, diabetes, dysfunction-associated fatty liver disease (MAFLD), cardiovascular disease, polycystic ovary syndrome (PCOS), abnormalities. Although no medication specifically approved treat IR, we summarized lifestyle changes pharmacological medications used as efficient intervention improve sensitivity. Ultimately, systematic discussion complex mechanism will help identify potential new targets closely

Language: Английский

Citations

428
Lipid droplet biogenesis and functions in health and disease DOI Open Access

Armella Zadoorian,

Ximing Du, Hongyuan Yang

et al.

Nature Reviews Endocrinology, Journal Year: 2023, Volume and Issue: 19(8), P. 443 - 459

Published: May 23, 2023

Language: Английский

Citations

275
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management DOI Creative Commons
Chengxu Ma, Xiaoni Ma, Conghui Guan

et al.

Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)

Published: May 14, 2022

Abstract Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent development CVDs T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control cardiovascular risk management (strict blood pressure lipid control), together recently developed glucose-lowering agents lipid-lowering drugs. This review mainly addresses important issues affecting choice antidiabetic lipid, antiplatelet treatments considering status patient. Finally, we also discuss changes therapy principles underlying T2DM.

Language: Английский

Citations

247
The crucial role and mechanism of insulin resistance in metabolic disease DOI Creative Commons
Xuefei Zhao, Xuedong An,

Cunqing Yang

et al.

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: March 28, 2023

Insulin resistance (IR) plays a crucial role in the development and progression of metabolism-related diseases such as diabetes, hypertension, tumors, nonalcoholic fatty liver disease, provides basis for common understanding these chronic diseases. In this study, we provide systematic review causes, mechanisms, treatments IR. The pathogenesis IR depends on genetics, obesity, age, drug effects. Mechanistically, any factor leading to abnormalities insulin signaling pathway leads host, including receptor abnormalities, disturbances internal environment (regarding inflammation, hypoxia, lipotoxicity, immunity), metabolic function organelles, other abnormalities. available therapeutic strategies are mainly exercise dietary habit improvement, chemotherapy based biguanides glucagon-like peptide-1, traditional Chinese medicine (e.g., herbs acupuncture) can also be helpful. Based current there still some vacancies follow up consider, is need define more precise biomarkers different lifestyle interventions, explore natural or synthetic drugs targeting treatment. This could enable treatment patients with multiple combined diseases, aim treating disease holistically reduce healthcare expenditures improve quality life extent.

Language: Английский

Citations

228
Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia DOI
Jéssica Ellen Barbosa de Freitas Lima, Natália Moreira, Elza Tiemi Sakamoto‐Hojo

et al.

Mutation Research/Genetic Toxicology and Environmental Mutagenesis, Journal Year: 2021, Volume and Issue: 874-875, P. 503437 - 503437

Published: Dec. 14, 2021

Language: Английский

Citations

112
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment DOI Creative Commons
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito

et al.

Pharmacological Research, Journal Year: 2022, Volume and Issue: 176, P. 106062 - 106062

Published: Jan. 10, 2022

Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors sodium-glucose co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal epithelium. The 2 (SGLT2) mainly expressed in S1 S2 segments tubule kidneys. Clinical guidelines recommend their use especially Type Diabetes mellitus (T2DM) patients with vascular complications and/or heart failure highlighting importance co-transporter (SGLT2i) pleiotropic effects. Interestingly, cognitive decline is widely recognized complication T2DM and, addition, to clarify its pathophysiology, there an urgent need understand how if diabetes therapies can control diabetes-related dysfunction. At time, although SGLT2 proteins present Central Nervous System (CNS), SGLT2i effects on impairments remain partly unknown. In pre-clinical studies, ameliorates dysfunction obese mice, reducing oxidative stress, neuroinflammation improving neuronal plasticity mitochondrial brain pathway. could bring back mTOR physiological state activation, stopping neurodegenerative diseases' onset or progression. Instead, clinical studies T2DM-related treated by much more limited. For these reasons, further needed better elucidate therapy affect decline. this scenario, review aims summarize knowledge role stimulate new trials.

Language: Английский

Citations

109
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus DOI Open Access
Georgia Xourafa,

Melis Korbmacher,

Michael Roden

et al.

Nature Reviews Endocrinology, Journal Year: 2023, Volume and Issue: 20(1), P. 27 - 49

Published: Oct. 16, 2023

Language: Английский

Citations

101
Polycystic ovary syndrome DOI
Elisabet Stener‐Victorin, Helena Teede, Robert J. Norman

et al.

Nature Reviews Disease Primers, Journal Year: 2024, Volume and Issue: 10(1)

Published: April 18, 2024

Language: Английский

Citations

96
Epigenetics of type 2 diabetes mellitus and weight change — a tool for precision medicine? DOI
Charlotte Ling, Karl Bacos, Tina Rönn

et al.

Nature Reviews Endocrinology, Journal Year: 2022, Volume and Issue: 18(7), P. 433 - 448

Published: May 5, 2022

Language: Английский

Citations

80
Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study DOI Open Access
Tiange Wang, Mian Li, Tianshu Zeng

et al.

Diabetes Care, Journal Year: 2022, Volume and Issue: 45(8), P. 1863 - 1872

Published: June 14, 2022

OBJECTIVE To investigate whether the association between insulin resistance and cardiovascular disease (CVD) differs by glucose tolerance status. RESEARCH DESIGN AND METHODS We analyzed a nationwide sample of 111,576 adults without CVD at baseline, using data from China Cardiometabolic Disease Cancer Cohort Study. Insulin was estimated sex-specific HOMA (HOMA-IR) quartiles for participants with normal tolerance, prediabetes, or diabetes, separately, 1 SD HOMA-IR overall study participants. used Cox proportional hazards models to examine incident according status evaluate risk associated combined categories obesity in prediabetes as compared tolerance. Models were adjusted age, sex, education attainment, alcohol drinking, smoking, physical activity, diet quality. RESULTS In diabetes defined three parameters, multivariable-adjusted hazard ratios (95% CIs) highest versus lowest quartile 1.03 (0.82–1.30), 1.23 (1.07–1.42), 1.61 (1.30–2.00), respectively; corresponding values per 1-SD increase 1.04 (0.92–1.18), 1.12 (1.06–1.18), 1.15 (1.09–1.21), respectively (P interaction = 0.011). Compared combination showed 17% CI 2–34%) higher CVD, while two nonobesity 15–17% lower CVD. upper exhibited 44–77% regardless Consistent findings observed different combinations glycemic parameters. CONCLUSIONS Glucose intolerance exacerbated risk. who both resistant obese risks related remained, obesity.

Language: Английский

Citations

75